株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

炎症性腸疾患(IBD):世界の治療薬産業および市場

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis

発行 Visiongain Ltd 商品コード 209072
出版日 ページ情報 英文 200 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=144.84円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
炎症性腸疾患(IBD):世界の治療薬産業および市場 Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2017-2027: Aminosalicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Crohn's Disease, Ulcerative Colitis
出版日: 2017年03月22日 ページ情報: 英文 200 Pages
概要

当レポートでは、世界の炎症性腸疾患市場の現状と将来見通しについて分析し、収益予測、成長率、市場シェア、SWOT・STEP分析、地域別動向などをまとめた結果をお届けします。

第1章 調査概要

第2章 炎症性腸疾患市場のイントロダクション

  • 炎症性腸疾患(IBD)とは?
  • IBDの分類
  • IBDの兆候および診断
  • IBDの多因子
  • IBDはどの程度一般的か?
  • IBDの治療オプションとは?
  • IBDの治療目標:目標達成に向けた治療へのアプローチ
  • 治療アルゴリズム:今後の方向性はトップダウン型アプローチか?

第3章 世界のIBD市場

  • IBD市場
  • 予測:バイオシミラーの影響は?
  • 生物学的療法の予測
  • アミノサリチル酸の予測
  • 抗生物質の予測
  • コルチコステロイドの予測
  • 免疫調節薬の予測

第4章 主要IBD治療薬の市場展望

  • Humira (AbbVie)
  • Remicade (Janssen Biotech)
  • Asacol (Actavis)
  • Pentasa (Shire)
  • Lialda (Shire)
  • Tysabri (Perrigo)
  • Xifaxan (Valeant)
  • Cimzia (UCB)
  • Entocort (AstraZeneca)
  • Neoral (Novartis)
  • Medrol (Pfizer)
  • Canasa (Allergan)
  • Apriso (Valeant) - Asacolへの挑戦?
  • Azulfidine (Pfizer)
  • Entyvio (武田薬品工業)
  • Simponi (Janssen Biotech)
  • Uceris (Valeant)

第5章 主要国市場:売上の展望

  • IBD治療薬:主要国市場
  • 米国のIBD治療薬市場:世界のリーダー
  • 日本のIBD治療薬市場:大幅に拡大
  • EU主要5カ国のIBD治療薬市場:英国が牽引
  • BRIC諸国のIBD治療薬市場:更なるシェア拡大

第6章 IBDのR&Dパイプライン

  • 主力の市販品およびパイプライン製品
  • インターロイキン(IL)阻害剤
  • 細胞接着分子(CAM)阻害剤
  • TNFアルファ阻害剤
  • 幹細胞治療:治療の基本
  • JAK阻害剤:新たな標的経路
  • トール容受容体作動薬
  • その他のエージェントクラス
  • バイオシミラー候補薬:主要生物製剤の有望な競合相手

第7章 IBD治療薬産業・市場の促進因子と阻害因子

  • IBD市場のSWOT・STEP分析
  • IBD市場の促進因子は?
  • 市場の阻害因子は?

第8章 IBD市場の主要企業

  • 最大企業:収益別
    • AbbVie
    • Janssen Biotech
    • Allergan
    • Shire Pharmaceuticals

第9章 結論

  • IBD市場の拡大予測
  • アミノサリチル酸およびその他の非生物学的治療
  • 生物学的治療が市場で優位
  • IBD治療における改善の必要性

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0178

The global inflammatory bowel diseases (IBD) drug market is estimated at $8.5bn in 2016 and $9.5bn in 2020. Biologic therapies are expected to be the main drivers of growth in the world IBD drug market over the forecast period. In 2016, the biologics submarket generated revenues of $5.8bn, accounting for 68% of the global IBD drug market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 200-page report you will receive 89 tables and 50 figures - all unavailable elsewhere.

The 200-page report provides clear detailed insight into the global inflammatory bowel diseases (IBD) drug market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

image1

Report Scope

  • Global Inflammatory Bowel Diseases (IBD) Drug Market forecasts from 2017-2027
  • Submarket forecasts from 2017-2027:
    • Biologics
    • Aminosalicylates
    • Antibiotics
    • Corticosteroids
    • Immunomodulators
  • Revenue forecast from 2017-2027 for 17 leading products:
    • Humira
    • Remicade
    • Lialda
    • Asacol
    • Pentasa
    • Xifaxan
    • Cimzia
    • Tysabri
    • Simponi
    • Canasa/Salofalk
  • - Entyvio
    • Apriso
    • Medrol
    • Neoral
    • Entocort
    • Uceris
    • Azulfidine
  • Revenue forecasts from 2017-2027 for 11 countries:
    • US
    • Japan
    • Germany, France, UK, Spain and Italy (EU5)
    • Brazil, Russia, India and China (BRIC)
  • Discussions on research and development, including drug candidates in these classes:
    • Interleukin (IL) inhibitors
    • Cell-adhesion molecule (CAM) inhibitors
    • TNF-alpha inhibitors
    • Stem cell therapies
    • JAK inhibitors
    • Toll-like receptor agonists
  • Assessment of selected leading companies that hold major market shares in the inflammatory bowel diseases drug industry
  • Discussions on trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT). It also analyses social, technological, economic and political factors influencing that industry and market (STEP)

Visiongain's study is intended for anyone requiring commercial analyses for the Global Inflammatory Bowel Diseases (IBD) Drug Market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 World IBD Drugs Market: Overview of Findings
  • 1.2 Why You Should Read This Report
  • 1.3 How the Study Delivers
  • 1.4 Main Questions Covered in the Analysis
  • 1.5 Who Is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Reports
  • 1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market

  • 2.1 What is Inflammatory Bowel Disease (IBD)?
  • 2.2 Classification of IBD
  • 2.3 Symptoms and Diagnosis of IBD
  • 2.4 Multifactorial Causes of IBD
  • 2.5 How Common is IBD?
  • 2.6 What Are the Treatment Options for IBD?
    • 2.6.1 Aminosalicylates - The Most Common therapy
    • 2.6.2 Antibiotics - Will There Be Any Supporting Evidence Soon?
    • 2.6.3 Corticosteroids - Uptake from Uceris?
    • 2.6.4 Immunomodulators - Slow to Act?
    • 2.6.5 Monoclonal Antibodies - Not cost-effective?
  • 2.7 Treatment Goals for IBD - Treat-to-Target Approach?
  • 2.8 Treatment Algorithm - is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2017-2027

  • 3.1 The Inflammatory Bowel Disease Market in 2016 and 2017
  • 3.2 Forecast 2017-2027: Impacted by Biosimilars?
  • 3.3 Biologic Therapies Forecast 2017-2027 - Driving the Market
  • 3.4 Aminosalicylates Forecast 2017-2027: The Work Horse of IBD Market
  • 3.5 Antibiotics Forecast 2017-2027: Growing Despite Challenges
  • 3.6 Corticosteroids Forecast 2017-2027: Driven by Uceris
  • 3.7 Immunomodulators Forecast 2017-2027 - Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2017-2027

  • 4.1 Humira (AbbVie) - Growing in the First Half of Forecast Period
    • 4.1.1 Humira: Forecast and Analysis, 2017-2027
  • 4.2 Remicade (Janssen Biotech) - Will Slowly be Eroded by Biosimilars
    • 4.2.1 Remicade: Forecast and Analysis, 2017-2027
  • 4.3 Asacol (Allergan) - Threat from Generic Competition
    • 4.3.1 Asacol: Forecast and Analysis, 2017-2027
  • 4.4 Pentasa (Shire) - Differentiated by Its Delivery System
    • 4.4.1 Pentasa: Forecast and Analysis, 2017-2027
  • 4.5 Lialda (Shire) - Will Improved Compliance Increase Revenue?
    • 4.5.1 Lialda: Forecast and Analysis, 2017-2027
  • 4.6 Tysabri (Perrigo) - Still Protected by Patent
    • 4.6.1 Tysabri: Forecast and Analysis, 2017-2027
  • 4.7 Xifaxan (Valeant) - Still Growing Significantly
    • 4.7.1 Xifaxan: Forecast and Analysis, 2017-2027
  • 4.8 Cimzia (UCB) - How Will It Fare Against Biosimilars?
    • 4.8.1 Cimzia: Forecast and Analysis, 2017-2027
  • 4.9 Entocort (AstraZeneca) - A Slow and Steady Decline?
    • 4.9.1 Entocort: Forecast and Analysis, 2017-2027
  • 4.10 Neoral (Novartis) - Will its Side Effect Profile Hamper Sales Growth?
    • 4.10.1 Neoral: Forecast and Analysis, 2017-2027
  • 4.11 Medrol (Pfizer) - Another Leading Steroid
    • 4.11.1 Medrol: Forecast and Analysis, 2017-2027
  • 4.12 Canasa (Allergan) - Will a Generic Competitor Soon Be Available?
    • 4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027
  • 4.13 Apriso (Valeant) - Challenger to Asacol?
    • 4.13.1 Apriso: Forecast and Analysis, 2017-2027
  • 4.14 Azulfidine (Pfizer) - Tried, Tested and Staying in the Market
    • 4.14.1 Azulfidine: Forecast and Analysis, 2017-2027
  • 4.15 Entyvio (Takeda Pharmaceuticals) - Driving the Biologics Segment
    • 4.15.1 Entyvio: Forecast and Analysis, 2017-2027
  • 4.16 Simponi (Janssen Biotech) - Rising Star for the Market?
    • 4.16.1 Simponi: Forecast and Analysis, 2017-2027
  • 4.17 Uceris (Valeant) - Meeting Patients' Needs with Its Delivery System
    • 4.17.1 Uceris: Forecast and Analysis, 2017-2027

5. Leading National Markets: Sales Outlooks, 2017-2027

  • 5.1 IBD Drugs - Leading National Markets 2016
  • 5.2 The US IBD Drug Market, 2017-2017 - The World Leader
  • 5.3 The Japanese IBD Drug Market, 2017-2027 - Growing Significantly?
  • 5.4 The EU-5 IBD Drug Market, 2017-2027 - Driven by the UK
    • 5.4.1 The German IBD Drug Market, 2017-2027
    • 5.4.2 The French IBD Drug Market, 2017-2027
    • 5.4.3 The UK IBD Drug Market, 2017-2027
    • 5.4.4 The Spanish IBD Drug Market, 2017-2027
    • 5.4.5 The Italian IBD Drug Market, 2017-2027
  • 5.5 IBD Drug Markets in BRIC Countries - Taking More Market Share
    • 5.5.1 The Brazilian IBD Drug Market, 2017-2027
    • 5.5.2 The Russian IBD Drug Market, 2017-2027
    • 5.5.3 The Indian Drug Market, 2017-2027
    • 5.5.4 The Chinese IBD Drug Market, 2017-2027

6. The R&D Pipeline for Inflammatory Bowel Disease, 2016

  • 6.1 Top Marketed and pipeline products - Launch dates and Patent expiry
  • 6.2 Interleukin (IL) Inhibitors - One of the Main Areas of Innovation
    • 6.2.1 CyCol (Sigmoid Pharma)
    • 6.2.2 PF-04236921 (Pfizer)
    • 6.2.3 QAX 576 (Novartis)
    • 6.2.4 TNF Kinoid (Neovacs)
    • 6.2.5 Vidofludimus (4SC) - Suspended
    • 6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)
  • 6.3 Cell-Adhesion Molecule (CAM) Inhibitors - A Promising Avenue
    • 6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)
    • 6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)
    • 6.3.3 MEDI 7183/AMG 181 (AstraZeneca)
    • 6.3.4 Etrolizumab (Roche)
    • 6.3.5 PF-00547659 (Pfizer)
    • 6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)
  • 6.4 TNF-α Inhibitors - a Specific Target
    • 6.4.1 AVX-470 (Avaxia Biologics)
    • 6.4.2 Ozoralizumab (ALX-0061, Ablynx)
  • 6.5 Stem Cell Therapies - Basis for a Cure?
    • 6.5.1 Ovasave (TxCell)
    • 6.5.2 MultiStem (Athersys and Pfizer)
    • 6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)
    • 6.5.4 Cx601 (TiGenix)
  • 6.6 JAK Inhibitors - New Target Pathway
    • 6.6.1 JNJ-54781532 (Janssen)
    • 6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)
  • 6.7 Toll-like Receptor Agonists
    • 6.7.1 BL-7040 (BioLineRX)
    • 6.7.2 Kappaproct (InDex Pharmaceuticals)
  • 6.8 Other Classes of Agent
    • 6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)
    • 6.8.2 GLPG0974 (Galapagos)
    • 6.8.3 RPC1063 (Receptos/now Celgene)
    • 6.8.4 SGX203 (Soligenix)
    • 6.8.5 Mongersen (GED-0301, Celgene)
    • 6.8.6 Tetomilast (OPC-6535, Otsuka)
    • 6.8.7 Laquinimod (Active Biotech)
    • 6.8.8 RHB-104 (RedHill Biopharma)
    • 6.8.9 Ozanimod (Celgene)
    • 6.8.10 GED-0301 (Celgene)
  • 6.9 Biosimilar Candidates - Promising Competitors of Leading Biologics
    • 6.9.1 Adalimumab Biosimilars
    • 6.9.2 Infliximab Biosimilars

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2016

  • 7.1 SWOT and STEP Analyses of the IBD Drugs Market
  • 7.2 What Factors Will Stimulate the IBD Market?
    • 7.2.1 Increasing Disease Incidence in Most National Markets
    • 7.2.2 Better Diagnosis - Early Referrals
    • 7.2.3 Delivery Systems Improve Existing Drugs
    • 7.2.4 Biological Drugs - Driving the Market Significantly
    • 7.2.5 Socioeconomic Costs of IBD
  • 7.3 What Factors Will Restrain the Market?
    • 7.3.1 Lack of Understanding of Disease Aetiology
    • 7.3.2 Compliance - Frequent Dosing is Inconvenient
    • 7.3.3 Limitations of Biologics - Side Effect Profiles
    • 7.3.4 The Possible Development of Alternative Treatments
    • 7.3.5 Surgery - Treatment for Recalcitrant IBD
    • 7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market, 2016

  • 8.1 The Largest Companies by Revenue
    • 8.1.1 AbbVie
    • 8.1.2 Janssen Biotech
    • 8.1.3 Allergan
    • 8.1.4 Shire Pharmaceuticals

9. Conclusions of the Study

  • 9.1 The IBD Drugs Market Will Expand from 2017 to 2027
  • 9.2 Aminosalicylates and Other Non-Biologic Treatments
  • 9.3 Biological Treatments Dominate the Market
  • 9.4 Improvements Needed in IBD Therapy
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1 Differentiating Crohn's Disease and Ulcerative Colitis
  • Table 2.2 Worldwide Prevalence Rates for IBD, 2016
  • Table 2.3 Worldwide Incidence Rates for IBD, 2016
  • Table 2.4 Geographical Variations in the Incidence of IBD, 2016
  • Table 2.5 Other Drug Types Used to Treat IBD, 2016
  • Table 2.6 Treatment Protocol for IBD, 2016
  • Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2016 and 2017
  • Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.4 Global IBD Drug Market Drivers and Restraints 2017-2027
  • Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.6 Global Biologic Therapies Drivers and Restraints, 2017-2027
  • Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.8 Global Aminosalicylates Drivers and Restraints, 2017-2027
  • Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.10 Global Antibiotics Drivers and Restraints, 2017-2027
  • Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027
  • Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 3.14 Global Immunomodulators Drivers and Restraints, 2017-2027
  • Table 4.1 Leading IBD Treatments by Revenue ($m), 2016
  • Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2016-2027
  • Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.4 Drivers and Restraints for Humira, 2017-2027
  • Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.6 Drivers and Restraints for Remicade, 2017-2027
  • Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.8 Drivers and Restraints for Asacol, 2017-2027
  • Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.10 Drivers and Restraints for Pentasa, 2017-2027
  • Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.12 Drivers and Restraints for Lialda, 2017-2027
  • Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.14 Drivers and Restraints for Tysabri, 2017-2027
  • Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.16 Drivers and Restraints for Xifaxan, 2017-2027
  • Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.18 Drivers and Restraints for Cimzia, 2017-2027
  • Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.20 Drivers and Restraints for Entocort, 2017-2027
  • Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.22 Drivers and Restraints for Neoral, 2017-2027
  • Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.24 Drivers and Restraints for Medrol, 2017-2027
  • Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.26 Drivers and Restraints for Canasa, 2017-2027
  • Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.28 Drivers and Restraints for Apriso, 2017-2027
  • Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.30 Drivers and Restraints for Azulfidine, 2017-2027
  • Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.32 Drivers and Restraints for Entyvio, 2017-2027
  • Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.34 Drivers and Restraints for Simponi, 2017-2027
  • Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.36 Drivers and Restraints for Uceris, 2017-2027
  • Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2016
  • Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021
  • Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027
  • Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.1 Key Patent dates for marketed and pipeline products
  • Table 6.2 Selected IL Inhibitors in Clinical Development, 2016
  • Table 6.3 Selected CAM Inhibitors in Clinical Development, 2016
  • Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2016
  • Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2016
  • Table 6.6 Selected JAK Inhibitors in Clinical Development, 2016
  • Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2016
  • Table 6.8 Selected Other Classes in Clinical Development, 2016
  • Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2016
  • Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2016
  • Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2016
  • Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2016
  • Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2016
  • Table 8.4 Allergan Revenues ($m) and Market Share (%), 2016
  • Table 8.5 Shire Revenues ($m) and Market Share (%), 2016
  • Table 9.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2016, 2021, 2027
  • Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2016, 2021, 2027

List of Figures

  • Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016
  • Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2016
  • Figure 3.2 Global IBD Drug Market Forecast ($m), 2016-2027
  • Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2027
  • Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2016-2027
  • Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2016-2027
  • Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2016-2027
  • Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2016-2027
  • Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2016-2027
  • Figure 4.1 World Humira Revenue Forecast ($m), 2016-2027
  • Figure 4.2 World Remicade Forecast ($m), 2016-2027
  • Figure 4.3 World Asacol Forecast ($m), 2016-2027
  • Figure 4.4 World Pentasa Forecast ($m), 2016-2027
  • Figure 4.5 World Lialda Forecast ($m), 2016-2027
  • Figure 4.6 World Tysabri Forecast ($m), 2016-2027
  • Figure 4.7 World Xifaxan Forecast ($m), 2016-2027
  • Figure 4.8 World Cimzia Forecast ($m), 2016-2027
  • Figure 4.9 World Entocort Forecast ($m), 2016-2027
  • Figure 4.10 World Neoral Forecast ($m), 2016-2027
  • Figure 4.11 World Medrol Forecast ($m), 2016-2027
  • Figure 4.12 World Canasa Forecast ($m), 2016-2027
  • Figure 4.13 World Apriso Forecast ($m), 2016-2027
  • Figure 4.14 World Azulfidine Forecast ($m), 2016-2027
  • Figure 4.15 World Entyvio Forecast ($m), 2016-2027
  • Figure 4.16 World Simponi Forecast ($m), 2016-2027
  • Figure 4.17 World Uceris Forecast ($m), 2016-2027
  • Figure 5.1 Global IBD Drug Market by Leading Country (%), 2016
  • Figure 5.2 Global IBD Drug Market by Leading Country (%), 2027
  • Figure 5.3 US IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2016-2027
  • Figure 5.6 German IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.7 French IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.8 UK IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2016-2027
  • Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.13 Russian IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.14 Indian IBD Drug Market Forecast ($m), 2016-2027
  • Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2016-2027
  • Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2016
  • Figure 8.2 AbbVie Assets - Marketed and Pipeline 2016
  • Figure 8.3 AbbVie Deals and Partnerships 2011 - 2016
  • Figure 8.4 Janssen Assets - Marketed and Pipeline 2016
  • Figure 8.5 Janssen - Deals and Partnerships 2011 - 2016
  • Figure 8.6 Allergan Assets - Marketed and Pipeline 2016
  • Figure 8.7 Allergan - Deals and Partnerships 2011 - 2016
  • Figure 8.8 Shire Assets - Marketed and Pipeline 2016
  • Figure 8.9 Shire - Deals and Partnerships 2011 - 2016

Companies Listed

  • 4SC
  • Abbott Laboratories
  • AbbVie
  • Ablynx
  • Actavis
  • Active Biotech
  • Ajinomoto
  • Allergan
  • Almirall
  • Amgen
  • Aptalis Pharmaceuticals
  • Astellas
  • AstraZeneca
  • Athersys
  • Atlantic Healthcare
  • Avaxia Biologics
  • BioLineRx
  • Biosafe
  • Boehringer Ingelheim
  • Calico
  • Celgene
  • Celltrion
  • Centocor Ortho Biotech
  • Coherus Biosciences
  • Coronado Biosciences
  • Cosmo Pharmaceuticals
  • Dr. Falk Pharma
  • Eddingpharm
  • Elan Pharmaceuticals
  • Epirus Biopharmaceuticals
  • Ferring
  • Forest Laboratories
  • Galapagos
  • Giaconda
  • Google
  • Harbor Biosciences
  • Hospira
  • InDex Pharmaceuticals
  • Infinity Pharmaceuticals
  • Isis Pharmaceuticals
  • Janssen Biotech
  • Johnson & Johnson
  • LG Sciences
  • MedImmune
  • Mochida
  • Mutare Health
  • Mylan Pharmaceuticals
  • Neovacs
  • Nisshin Kyorin
  • Nogra Pharma
  • Novartis
  • Oncobiologics
  • Ortho Biotech
  • Osiris Therapeutics
  • Otsuka
  • Ovamed
  • Palau Pharma
  • Pendopharm
  • Perrigo
  • Pfizer
  • Pharmascience
  • Pluristem Therapeutics
  • Quest Diagnostics
  • Ranbaxy Laboratories
  • Receptos
  • RedHill Biopharma
  • Reliance Life Sciences
  • Roche
  • Salix Pharmaceuticals
  • Sandoz
  • Sanofi
  • Santarus
  • Sequella
  • Shire Pharmaceuticals
  • Sigmoid Pharma
  • Soligenix
  • SonarMD
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical Industries
  • TiGenix
  • Toray Industries
  • TxCell
  • UCB
  • Valeant
  • Warner Chilcott
  • Zydus Cadila

List of Organisations Mentioned in the Report

  • Center for Human Disease Research, Leiden
  • Centrale Commissie Mensgebonden Onderzoek (CCMO)
  • Centres for Disease Control and Prevention (US)
  • Crohn's and Colitis Foundation of Canada
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Georgia State University
  • Hebrew University of Jerusalem
  • Institut National de la Santé et de la Recherche Médicale (INSERM)
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • Karolinska Institute
  • National Health Service (UK NHS)
  • National Institute for Health and Care Excellence (UK NICE)
  • National Institutes of Health (US NIH)
  • Servicio Sanitario Nazionale (SSN, Italy)
  • The Crohn's and Colitis UK Foundation
  • The European Federation of Crohn's and Ulcerative Colitis Associations
Back to Top